Published in Carcinogenesis on September 09, 2004
Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci U S A (2005) 1.78
Dietary agents for chemoprevention of prostate cancer. Cancer Lett (2008) 1.72
Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine (2010) 1.37
Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer (2010) 1.26
Inhibition of carcinogenesis by tea constituents. Semin Cancer Biol (2007) 1.25
Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer (2009) 1.22
Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res (2009) 1.21
Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst (2009) 1.19
Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr (2011) 1.00
New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer (2011) 0.98
Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence. J Carcinog (2011) 0.97
Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Mol Oncol (2007) 0.97
Chemoprevention of prostate cancer by d,l-sulforaphane is augmented by pharmacological inhibition of autophagy. Cancer Res (2013) 0.97
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One (2008) 0.94
Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis. Adv Cancer Res (2009) 0.93
Lack of evidence for green tea polyphenols as DNA methylation inhibitors in murine prostate. Cancer Prev Res (Phila) (2009) 0.90
Green tea and prostate cancer: from bench to clinic. Front Biosci (Elite Ed) (2009) 0.88
The strategies to control prostate cancer by chemoprevention approaches. Mutat Res (2014) 0.87
Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer (2004) 0.87
Anticancer activity of green tea polyphenols in prostate gland. Oxid Med Cell Longev (2012) 0.84
Cancer prevention by tocopherols and tea polyphenols. Cancer Lett (2013) 0.82
Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth. Mol Endocrinol (2012) 0.81
EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism. Sci Rep (2015) 0.80
Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice. Cancer Prev Res (Phila) (2014) 0.79
The association of tea consumption and the risk and progression of prostate cancer: a meta-analysis. Int J Clin Exp Med (2014) 0.78
mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. J Cell Physiol (2012) 0.78
The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model. Cancer Prev Res (Phila) (2015) 0.77
Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009 - present). Expert Opin Ther Pat (2012) 0.76
Lessons learned from cancer prevention studies with nutrients and non-nutritive dietary constituents. Mol Nutr Food Res (2016) 0.76
Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention. Transl Med (Sunnyvale) (2012) 0.75
Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer. PLoS One (2017) 0.75
Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges. Antioxidants (Basel) (2017) 0.75
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol (2013) 2.84
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol (2009) 2.71
Management of stage T1 tumors of the bladder: International Consensus Panel. Urology (2005) 1.81
Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol (2011) 1.62
Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol (2008) 1.51
Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst (2009) 1.19
Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology (2008) 1.19
Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. Cancer Metastasis Rev (2008) 1.15
Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. Cancer Res (2004) 1.14
The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer (2010) 1.12
Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer (2004) 1.05
Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Mol Oncol (2007) 0.97
Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent. Cancer Res (2004) 0.96
Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol (2004) 0.96
A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS One (2008) 0.94
Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int (2014) 0.93
Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene (2002) 0.93
Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis. Adv Cancer Res (2009) 0.93
Clusterin (CLU) and lung cancer. Adv Cancer Res (2009) 0.92
Epigenetic DNA-methylation regulation of genes coding for lipid raft-associated components: a role for raft proteins in cell transformation and cancer progression (review). Oncol Rep (2007) 0.91
Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis. Cancer Res (2007) 0.88
Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling. Carcinogenesis (2005) 0.88
Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Physiol (2009) 0.87
Polyphenon E(R), a standardized green tea extract, induces endoplasmic reticulum stress, leading to death of immortalized PNT1a cells by anoikis and tumorigenic PC3 by necroptosis. Carcinogenesis (2013) 0.87
Nuclear clusterin accumulation during heat shock response: implications for cell survival and thermo-tolerance induction in immortalized and prostate cancer cells. J Cell Physiol (2006) 0.87
Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis. Endocrinology (2002) 0.86
Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol (2013) 0.86
Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch (2002) 0.86
Upregulation of clusterin in prostate and DNA damage in spermatozoa from bisphenol A-treated rats and formation of DNA adducts in cultured human prostatic cells. Toxicol Sci (2011) 0.85
Clusterin (CLU) and prostate cancer. Adv Cancer Res (2009) 0.85
Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin. Biochem J (2004) 0.84
Anticancer activity of green tea polyphenols in prostate gland. Oxid Med Cell Longev (2012) 0.84
European Study of Radical Prostatectomy: time trends in Europe, 1993-2005. BJU Int (2007) 0.83
Clusterin decreases oxidative stress in lung fibroblasts exposed to cigarette smoke. Am J Respir Crit Care Med (2006) 0.83
Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel. Tumour Biol (2011) 0.82
Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells. Int J Oncol (2011) 0.82
B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: implications for cell survival. Blood Cells Mol Dis (2007) 0.82
Mitostatin is down-regulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. PLoS One (2011) 0.81
Chapter 2: Clusterin (CLU): From one gene and two transcripts to many proteins. Adv Cancer Res (2009) 0.81
Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin. Carcinogenesis (2005) 0.80
Chronic administration of green tea extract to TRAMP mice induces the collapse of Golgi apparatus in prostate secretory cells and results in alterations of protein post-translational processing. Int J Oncol (2011) 0.80
Establishment of an organotypic in vitro culture system and its relevance to the characterization of human prostate epithelial cancer cells and their stromal interactions. Pathol Res Pract (2007) 0.80
Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Res (2003) 0.80
The future of urology. Eur Urol (2011) 0.79
Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). BJU Int (2011) 0.79
Chapter 3: The shifting balance between CLU forms during tumor progression. Adv Cancer Res (2009) 0.79
Prognostic role of clusterin in resected adenocarcinomas of the lung. Lung Cancer (2012) 0.78
mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. J Cell Physiol (2012) 0.78
Cisplatin-resistance modulates the effect of protein synthesis inhibitors on spermidine/spermine N(1)-acetyltransferase expression. Int J Biochem Cell Biol (2004) 0.77
Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth. J Med Chem (2014) 0.77
Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides. J Proteome Res (2014) 0.77
Creating prodynorphin-expressing stem cells alerted for a high-throughput of cardiogenic commitment. Regen Med (2007) 0.76
Radical cystectomy for BCG failure: has the timing improved in recent years? BJU Int (2011) 0.75
Hyper-homocysteinemia alters amyloid peptide-clusterin interactions and neuroglial network morphology and function in the caudate after intrastriatal injection of amyloid peptides. Curr Alzheimer Res (2007) 0.75
Collateral activity of immunotherapy with bacillus Calmette-Guérin for the treatment of non-muscle-invasive transitional cell carcinoma of the bladder: new insights. Eur Urol (2012) 0.75
Editorial comment on: P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol (2007) 0.75
High surgical volume, high quality, and low costs: a perfect combination. Is it always possible in patients who need radical prostatectomy? Eur Urol (2006) 0.75
Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us? Urol Oncol (2011) 0.75
5A prospective survey of current prostate biopsy practices among oncological urologists. Can J Urol (2010) 0.75
Correction to "Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides". J Proteome Res (2016) 0.75